Access to healthcare
We want to help secure a future where all people have access to affordable, sustainable healthcare. This is critical for the prevention and early diagnosis of disease as well as to deliver life-changing treatments – for healthy people and a healthy society.
Our approach to Access to healthcare
We are committed to supporting society through some of its toughest healthcare challenges. We work in collaboration with governments, academia, international and local organisations, and other stakeholders, and we always put patients first. Our response to the COVID-19 pandemic, with a focus on low and middle-income countries, is one example of our equitable access strategy in action.
We provide healthcare solutions across the patient care pathway - from prevention, raising awareness, diagnosis and treatment, to post-treatment support.
Our focus areas
Embedding practices into our product portfolio to drive equitable access to healthcare — including digital health, clinical trial diversity, patient centricity, investment in rare diseases, open innovation and IP-sharing arrangements.
Affordability and pricing
Drive accessibility of medicines for diverse, equitable and inclusive patient groups, through company policy and programming, including core pricing principles and access programmes
Health system resilience
Strengthen health systems through advocacy, build capabilities to address unmet medical need, improve access to quality healthcare, and provide solutions along a care continuum from prevention to post-treatment; commit to disaster relief, grants and donations.
Our ambition by 2025:
Reach 50 million
people (cumulatively) through our Healthy Heart Africa, Healthy Lung and Young Health Programme*
healthcare workers (cumulatively) to strengthen health systems throughout the world through our Healthy Heart Africa, Healthy Lung and Young Health Programme*
through cross-sectoral partnerships to improve health outcomes
people reached through Access to Healthcare programmes including Healthy Heart Africa, Young Health Programme and Healthy Lung*
healthcare workers and others trained since 2010*
people reached through our patient assistance programmes(cumulative) which help patients in financial difficulty gain access to our medications*
*as of December 2021, source: Sustainability Report
Young Health Programme
Since 2010, our Young Health Programme has worked to help young people aged 10-24 take proactive control of their health, especially to combat long-term conditions like cancer, diabetes, respiratory and heart disease, and ill mental health – often called non-communicable diseases. Through research, advocacy, and our disease prevention schemes, we are helping young people make better health choices for brighter life chances.
Partnership for Health System Sustainability and Resilience
Launched in 2020 and expanded in 2021, the Partnership for Health System Sustainability and Resilience (PHSSR) is a collaboration between AstraZeneca, the London School of Economics, and the World Economic Forum, to strengthen global health systems and improve population health.
Healthy Heart Africa
Our Healthy Heart Africa programme is committed to tackling hypertension and the increasing burden of cardiovascular disease across Africa. We are committed to reaching 10 million people with elevated blood pressure across Africa by 2025, working with local and global partners to train providers, increase education and awareness, and facilitate access to low-cost anti-hypertensives where applicable.